PANBELA THERAPEUTICS INC (PBLA) Fundamental Analysis & Valuation

NASDAQ:PBLA • US69833W4042

Current stock price

1.11 USD
-0.12 (-9.76%)
At close:
1.04 USD
-0.07 (-6.31%)
After Hours:

This PBLA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PBLA Profitability Analysis

1.1 Basic Checks

  • PBLA had negative earnings in the past year.
  • PBLA had a negative operating cash flow in the past year.
PBLA Yearly Net Income VS EBIT VS OCF VS FCFPBLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of PBLA (-221.35%) is worse than 92.42% of its industry peers.
Industry RankSector Rank
ROA -221.35%
ROE N/A
ROIC N/A
ROA(3y)-276.27%
ROA(5y)-267.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PBLA Yearly ROA, ROE, ROICPBLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 1K -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PBLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PBLA Yearly Profit, Operating, Gross MarginsPBLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PBLA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, PBLA has more shares outstanding
  • PBLA has a worse debt/assets ratio than last year.
PBLA Yearly Shares OutstandingPBLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5K 10K 15K 20K 25K
PBLA Yearly Total Debt VS Total AssetsPBLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -22.59, we must say that PBLA is in the distress zone and has some risk of bankruptcy.
  • PBLA's Altman-Z score of -22.59 is on the low side compared to the rest of the industry. PBLA is outperformed by 89.56% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.59
ROIC/WACCN/A
WACCN/A
PBLA Yearly LT Debt VS Equity VS FCFPBLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • A Current Ratio of 0.21 indicates that PBLA may have some problems paying its short term obligations.
  • The Current ratio of PBLA (0.21) is worse than 97.98% of its industry peers.
  • A Quick Ratio of 0.21 indicates that PBLA may have some problems paying its short term obligations.
  • PBLA has a worse Quick ratio (0.21) than 97.81% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
PBLA Yearly Current Assets VS Current LiabilitesPBLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PBLA Growth Analysis

3.1 Past

  • The earnings per share for PBLA have decreased strongly by -67.23% in the last year.
EPS 1Y (TTM)-67.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PBLA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.41%
EPS Next 2Y41.21%
EPS Next 3Y25.88%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PBLA Yearly Revenue VS EstimatesPBLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 200M 400M 600M 800M
PBLA Yearly EPS VS EstimatesPBLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10K -20K -30K

More info and screens

Find the best growth stocksShow best growing peers

1

4. PBLA Valuation Analysis

4.1 Price/Earnings Ratio

  • PBLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PBLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PBLA Price Earnings VS Forward Price EarningsPBLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PBLA Per share dataPBLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1K -2K -3K -4K

4.3 Compensation for Growth

  • PBLA's earnings are expected to grow with 25.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.21%
EPS Next 3Y25.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PBLA Dividend Analysis

5.1 Amount

  • No dividends for PBLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PBLA Fundamentals: All Metrics, Ratios and Statistics

PANBELA THERAPEUTICS INC

NASDAQ:PBLA (3/6/2024, 8:15:57 PM)

After market: 1.04 -0.07 (-6.31%)

1.11

-0.12 (-9.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-14
Earnings (Next)05-02
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners50.67%
Ins Owner Change0%
Market Cap1.41M
Revenue(TTM)N/A
Net Income(TTM)-23.53M
Analysts82.5
Price Target418.2 (37575.68%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.88%
Min EPS beat(2)-65.74%
Max EPS beat(2)-28.02%
EPS beat(4)0
Avg EPS beat(4)-40.7%
Min EPS beat(4)-65.74%
Max EPS beat(4)-18.74%
EPS beat(8)1
Avg EPS beat(8)-85.77%
EPS beat(12)3
Avg EPS beat(12)-61.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1900%
EPS NQ rev (1m)1.06%
EPS NQ rev (3m)-1878.86%
EPS NY rev (1m)0.84%
EPS NY rev (3m)-1883.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4010.88
EYN/A
EPS(NY)-35.07
Fwd EYN/A
FCF(TTM)-21.39
FCFYN/A
OCF(TTM)-21.39
OCFYN/A
SpS0
BVpS-1.95
TBVpS-1.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -221.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-276.27%
ROA(5y)-267.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -22.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.65%
EPS Next Y96.41%
EPS Next 2Y41.21%
EPS Next 3Y25.88%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.17%
EBIT Next 3Y3.08%
EBIT Next 5Y8.69%
FCF growth 1Y-338.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-338.93%
OCF growth 3YN/A
OCF growth 5YN/A

PANBELA THERAPEUTICS INC / PBLA Fundamental Analysis FAQ

What is the fundamental rating for PBLA stock?

ChartMill assigns a fundamental rating of 0 / 10 to PBLA.


What is the valuation status of PANBELA THERAPEUTICS INC (PBLA) stock?

ChartMill assigns a valuation rating of 1 / 10 to PANBELA THERAPEUTICS INC (PBLA). This can be considered as Overvalued.


Can you provide the profitability details for PANBELA THERAPEUTICS INC?

PANBELA THERAPEUTICS INC (PBLA) has a profitability rating of 0 / 10.


What is the financial health of PANBELA THERAPEUTICS INC (PBLA) stock?

The financial health rating of PANBELA THERAPEUTICS INC (PBLA) is 0 / 10.